AceLink new logo

Yuqiao (Jerry) Shen, Ph.D.

Chief Executive Officer, Co-founder

Dr. Shen brings more than 20 years of pharmaceutical drug development experience spanning from early discovery to phase 3 clinical trials.  Before founding AceLink in 2018, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development.  He joined BioMarin in 2010 when the company acquired LEAD Therapeutics, a drug discovery company where he served as VP of Drug Discovery Biology.   Prior to LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded.  Prior to that, he worked at Onyx Pharmaceuticals, where he served at positions with increasing responsibilities and helped development of oncolytic viruses and gene delivery viral vectors.

Dr. Shen holds B.S. in Physiology from Fudan University, Ph.D. in Molecular Biology from State University of New York at Buffalo, and received post-doctoral training at Princeton University.  He has co-authored more than 35 peer-reviewed papers, is a co-inventor in more than 30 issued and pending patents.  In 2018, Talazoparib, a cancer drug for which he spent many years of his career both at LEAD and at BioMarin, received marketing approval from FDA.

© Copyright AceLink Therapeutics. All rights reserved

1 comment

Leave a comment

Your email address will not be published.